en · de · es · fr · pt
faq-desk.peptides7250.com › Topic › Structure And Receptor Pharmacology — 2026 Update

Structure And Receptor Pharmacology — 2026 Update

By Editorial Desk · published 2025-10-19 · last reviewed 2025-12-07 · Topic

GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-12-07 and is reviewed periodically as new material appears.

Structure And Receptor Pharmacology

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Handling Storage And Analytical Methods

Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.

Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.

Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.

Cjc-1295 at a glance

PropertyValueNotes
Peptide classSynthetic GHRH analogueBuilt on a 29 residue sequence
Primary targetGHRH receptor (GHRHR)Class B G protein coupled receptor
Unconjugated half lifeMinutesLimited by protease degradation
Key modificationFour residue substitutionsPositions 2, 8, 15 and 27
Common synonymModified GRF(1-29)Usually denotes the form without DAC

Albumin Binding and Duration of Action

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

Related pages on this site

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Receptor Action and Pharmacokinetics

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

Further detail

==== Multiple bodies per grave ==== Some couples or groups of people (such as a married couple or other family members) may wish to be buried in the same plot. In some cases, the coffins (or urns) may simply be buried side by side. In others, one casket may be interred above another. If this is planned for in advance, the first casket may be buried more deeply than is the usual practice so that the second casket may be placed over it without disturbing the first. In many states in Australia all graves are designated two or three depth (depending on the water table) for multiple burials, at the discretion of the burial rights holder, with each new interment atop the previous coffin separated by a thin layer of earth. As such all graves are dug to greater depth for the initial burial than the traditional six feet to facilitate this practice. Mass burial is the practice of burying multiple bodies in one location. Civilizations attempting genocide often employ mass burial for victims. However, mass burial may in many cases be the only practical means of dealing with an overwhelming number of human remains, such as those resulting from a natural disaster, an act of terrorism, an epidemic, or an accident. This practice has become less common in the developed world with the advent of genetic testing, but even in the 21st century remains which are unidentifiable by current methods may be buried in a mass grave. Individuals who are buried at the expense of the local authorities and buried in potter's fields may be buried in mass graves.

Healthy diet (a diet with limited refined carbohydrates, added sugars, trans fats, as well as limited intake of sodium and total calories) Physical fitness (30–45 minutes of cardiovascular exercise per day, 3–5 days a week) Weight loss by as little as 5–10 percent may have a significant impact on overall health

== B == B-cell lymphoma – B cells – B lymphocytes (B cells) – bactericidal – bacteriostatic – bacterium – baculovirus – baseline – basophil – bDNA test – beta-2 microglobulin (β2M) – bilirubin – bioavailability – biological response modifiers (BRMs) – biopsy – biotechnology – blinded study – blips – blood–brain barrier – body fat redistribution (BFR) syndrome – body fluids – bone marrow – bone marrow suppression – booster – branched DNA assay – breakthrough infection – Broadway Cares/Equity Fights AIDS – bronchoscopy – budding – buffalo hump – bugchasing and giftgiving – Burkitt's lymphoma

Alsactide (INN; brand name Synchrodyn 1-17 or simply Synchrodyn; former development code Hoechst 433; also known as alisactide) is a synthetic peptide and analogue of adrenocorticotropic hormone (ACTH) which is used in Italy as a diagnostic agent in kidney function for adrenal insufficiency. Like ACTH, alsactide is thought to act as a non-selective agonist of the melanocortin receptors, including the ACTH receptor (MC2R). However, it appears to show a different profile of receptor selectivity relative to ACTH, as it apparently demonstrated no evidence of inhibition of endogenous ACTH in Addison's disease patients.

The scientific name Octopoda was first given as the order of octopuses in 1818 by English biologist William Elford Leach, who classified them as Octopoida the previous year. Octopoda consists of around 300 known species and were historically divided into two suborders, the Incirrina and the Cirrina. More recent evidence suggests cirrates are the most basal species, not a unique clade. The incirrate octopuses (the majority of species) lack the cirri and paired swimming fins of the cirrates. In addition, the internal shell of incirrates is either present as a pair of stylets or absent altogether.

Sources: en.wikipedia.org

Supporting material

=== Macrocycles === Macrocycles are a traditional component in supramolecular chemistry. The macrocyclic effect enhances otherwise weak interactions. Cyclodextrins, calixarenes, cucurbiturils, and crown ethers allow the incorporation of alkali metal cations. More complex, 3-dimenesion receptors include cyclophanes, and cryptands. Supramolecular metallocycles and metallacrowns are related components. Common metallocycle shapes in these types of applications include triangles, squares, and pentagons, each bearing functional groups that connect the pieces via "self-assembly."

Singer noted in 1949 that Psilocybe cubensis had psychoactive properties. In Australia, the use of psychoactive mushrooms grew rapidly between 1969 and 1975. In a 1992 paper, locals and tourists in Thailand were reported to consume P. cubensis and related species in mushroom omelets—particularly in Ko Samui and Ko Pha-ngan. At times, omelets were adulterated with LSD, resulting in prolonged intoxication. A thriving subculture had developed in the region. Other localities, such as Hat Yai, Ko Samet, and Chiang Mai, also had some reported usage. In 1996, jars of honey containing Psilocybe cubensis were confiscated at the Dutch-German border. Upon examination, it was revealed that jars of honey containing psychedelic mushrooms were being sold at Dutch coffee shops. P. cubensis is one of the most widely known of the psilocybin-containing mushrooms used for triggering psychedelic experiences after ingestion. Its major alkaloids are:

As a salt, its dominant use is as an emulsifier for the emulsion polymerization of fluoropolymers such as PTFE, polyvinylidene fluoride, and fluoroelastomers. For this use, 3M subsidiary Dyneon has a replacement emulsifer despite DuPont stating PFOA is an "essential processing aid". In the past PFOA was used in the production of Gore-Tex as it is PTFE-based. In PTFE processing, PFOA is in aqueous solution and forms micelles that contain tetrafluoroethylene and the growing polymer. PFOA can be used to stabilize fluoropolymer and fluoroelastomer suspensions before further industrial processing and in ion-pair reversed-phase liquid chromatography it can act as an extraction agent. PFOA also finds uses in electronic products and as an industrial fluorosurfactant. In a 2009 EPA study of 116 products, purchased between March 2007 and May 2008 and found to contain at least 0.01% fluorine by weight, the concentrations of PFOA were determined. Concentrations shown below range from not detected, or ND, (with the detection limit in parentheses) to 6750 with concentrations in nanograms of PFOA per gram of sample (parts per billion) unless stated otherwise.

=== Chesapeake Bay restoration === Moore said he would support Chesapeake Bay restoration efforts by promoting "accountability and enforcement" in Maryland, as well as in neighboring states, use federal funds to upgrade water and wastewater systems, and by increasing the number of environmental inspectors. In October 2022, he told Lancaster Farming that he would develop a plan to accelerate projects to improve water quality and cut carbon emissions in his administration's first 100 days, and supported the restoration of the state's Chesapeake Bay Restoration Fund. In July 2023, Moore signed executive orders to refocus cleanup efforts onto shallow areas of the bay and to establish the Council on the Chesapeake and Coastal Bays to research state policy on oyster restoration and harvesting. From October 2023 to December 2025, Moore served as the chair of the Chesapeake Executive Council. During the 2025 legislative session, Moore introduced the Bay Legacy Act, which would promote regenerative farming practices on public lands, increase support for agricultural and oyster farmers, and improve the Maryland Department of Natural Resources's water quality monitoring methods. The Bay Legacy Act passed and was signed into law by Moore in May 2025. In December 2025, Moore, Delaware Governor Matt Meyer, Virginia Governor Glenn Youngkin, and Pennsylvania Governor Josh Shapiro approved a new cleanup plan that extended the Chesapeake Bay restoration effort to 2040 and includes commitments to reducing sediment pollution to the Bay.

Sources: en.wikipedia.org

Notes from published material

== Industrial applications == Although the use of protecting groups is not preferred in industrial syntheses, they are still used in industrial contexts, e.g. sucralose (sweetener) or the Roche synthesis of oseltamivir (Tamiflu, an antiviral drug) An important example of industrial applications of protecting group theory is the synthesis of ascorbic acid (Vitamin C) à la Reichstein.

=== Usage controversy and regulation === Dextropropoxyphene is subject to some controversy; while many physicians prescribe it for a wide range of mildly to moderately painful symptoms, as well as for treatment of diarrhea, many others refuse to prescribe it, citing limited effectiveness. In addition, the therapeutic index of dextroproxyphene is relatively narrow. Caution should be used when administering dextropropoxyphene, particularly with children and the elderly and with patients who may be pregnant or breastfeeding; other reported problems include kidney, liver, or respiratory disorders, and prolonged use. Attention should be paid to concomitant use with tranquillizers, antidepressants, or excess alcohol. Darvon, a dextropropoxyphene formulation made by Eli Lilly, which had been on the market for 25 years, came under scrutiny in 1978 by consumer groups that said it was associated with suicide. Darvon was never withdrawn from the market, until recently, but Lilly has waged a sweeping, and largely successful, campaign among doctors, pharmacists, and Darvon users to defend the drug as safe when it is used in proper doses and not mixed with alcohol. After determining the risks outweigh the benefits, the US FDA requested physicians stop prescribing the drug. On November 19, 2010, the FDA announced that Xanodyne Pharmaceuticals agreed to withdraw Darvon and Darvocet in the United States, followed by manufacturers of dextropropoxyphene.

== History == Mycophenolic acid was discovered by Italian medical scientist Bartolomeo Gosio. Gosio collected a fungus from spoiled corn and named it Penicillium glaucum. (The species is now called P. brevicompactum.) In 1893 he found that the fungus had antibacterial activity. In 1896 he isolated crystals of the compound, which he successfully demonstrated as the active antibacterial compound against the anthrax bacterium. This was the first antibiotic that was isolated in pure and crystalline form. But the discovery was forgotten. It was rediscovered by two American scientists C.L. Alsberg and O.M. Black in 1912, and given the name mycophenolic acid. The compound was eventually demonstrated to have antiviral, antifungal, antibacterial, anticancer, and antipsoriasis activities. Although it is not commercialised as antibiotic due to its adverse effects, its modified compound (ester derivative) is an approved immunosuppressant drug in kidney, heart, and liver transplantations, and is marketed under the brands Cellcept (mycophenolate mofetil by Roche) and Myfortic (mycophenolate sodium by Novartis). Cellcept was developed by a South African geneticist Anthony Allison and his wife Elsie M. Eugui. In the 1970s while working at the Medical Research Council, Allison investigated the biochemical causes of immune deficiency in children. He discovered the metabolic pathway involving an enzyme, inosine monophosphate dehydrogenase, which is responsible for undesirable immune response in autoimmune diseases, as well as for immune rejection in organ transplantation.

=== Computational community surveillance === One of the key tools identified by the WHO and others for the fight against rising antimicrobial resistance is improved surveillance of the spread and movement of AMR genes through different communities and regions. Recent advances in high-throughput DNA sequencing as a result of the Human Genome Project have resulted in the ability to determine the individual microbial genes in a sample. Along with the availability of databases of known antimicrobial resistance genes, such as the Comprehensive Antimicrobial Resistance Database (CARD) and ResFinder, this allows the identification of all the antimicrobial resistance genes within the sample – the so-called "resistome". In doing so, a profile of these genes within a community or environment can be determined, providing information into how antimicrobial resistance is spreading through a population and allowing for the identification of resistance that is of concern.

Tight scaly skin (Ichthyosis) Absence of ABCA12 gene (Ichthyosis) Swollen or puffy gums (Periodontitis/Gingivitis) Purulent drainage from lips (Improper Wound healing) Wide mouth which causes difficulty feeding and suckling Difficulty in feeding causes lack of adequate nutrition, dehydration and even death Skin that is more prone to infection Hindered pulmonary ventilation Hindered pulmonary ventilation

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

What does the acronym DAC refer to?

DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.

Does this peptide occur naturally in the body?

No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.

How should the dry powder be stored?

Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.

Network